OM:SENZA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

SenzaGen AB markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals, complex mixtures, and cosmetic ingredients in Sweden and internationally.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has SenzaGen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SENZA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.9%

SENZA

2.9%

SE Biotechs

5.0%

SE Market


1 Year Return

-46.8%

SENZA

10.7%

SE Biotechs

10.9%

SE Market

Return vs Industry: SENZA underperformed the Swedish Biotechs industry which returned 10.7% over the past year.

Return vs Market: SENZA underperformed the Swedish Market which returned 10.9% over the past year.


Shareholder returns

SENZAIndustryMarket
7 Day0.9%2.9%5.0%
30 Day6.3%9.0%12.7%
90 Day-6.4%21.5%1.4%
1 Year-45.5%-46.8%11.5%10.7%12.5%10.9%
3 Yearn/a27.1%23.9%16.4%0.7%
5 Yearn/a80.3%68.7%36.4%9.5%

Price Volatility Vs. Market

How volatile is SenzaGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SenzaGen undervalued compared to its fair value and its price relative to the market?

2.54x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SENZA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SENZA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SENZA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SENZA is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SENZA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SENZA is good value based on its PB Ratio (2.5x) compared to the SE Biotechs industry average (6.2x).


Next Steps

Future Growth

How is SenzaGen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SenzaGen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has SenzaGen performed over the past 5 years?

-45.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SENZA is currently unprofitable.

Growing Profit Margin: SENZA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SENZA is unprofitable, and losses have increased over the past 5 years at a rate of -45.5% per year.

Accelerating Growth: Unable to compare SENZA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SENZA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: SENZA has a negative Return on Equity (-37.43%), as it is currently unprofitable.


Next Steps

Financial Health

How is SenzaGen's financial position?


Financial Position Analysis

Short Term Liabilities: SENZA's short term assets (SEK123.6M) exceed its short term liabilities (SEK5.7M).

Long Term Liabilities: SENZA's short term assets (SEK123.6M) exceed its long term liabilities (SEK3.1M).


Debt to Equity History and Analysis

Debt Level: SENZA is debt free.

Reducing Debt: SENZA has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SENZA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SENZA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.1% each year


Next Steps

Dividend

What is SenzaGen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SENZA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SENZA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SENZA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SENZA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SENZA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Axel Sjöblad (52yo)

1

Tenure

kr2,229,600

Compensation

Mr. Axel Sjöblad, MBA. EMBA has been Chief Executive Officer of SenzaGen AB. since June 17, 2019. Mr. Sjöblad was Managing Director of BioGaia AB from March 1, 2016 to June 30, 2018. Mr. Sjöblad serves as  ...


CEO Compensation Analysis

Compensation vs Market: Axel's total compensation ($USD240.60K) is about average for companies of similar size in the Swedish market ($USD222.28K).

Compensation vs Earnings: Insufficient data to compare Axel's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Axel Sjöblad
Chief Executive Officer1yrkr2.23m0.021% SEK71.8k
Peter Nählstedt
Acting VP of Sales & Director2.42yrskr100.00k0.0053% SEK18.2k
Marianne Olsson
Vice President of Finance3.58yrsno data0.54% SEK1.8m
Maria Agemark
Vice President of Operations2.42yrsno data0.35% SEK1.2m
Henrik Johansson
Chief Scientist0.42yrno data0.0025% SEK8.4k
Mikael Wahlgren
Chief Legal Officer3.42yrsno data0.040% SEK136.7k
Tina Lawesson
Vice President of Marketing & Communications.1.5yrsno datano data

1.5yrs

Average Tenure

51yo

Average Age

Experienced Management: SENZA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Peter Nählstedt
Acting VP of Sales & Director2.42yrskr100.00k0.0053% SEK18.2k
Carl Arne Borrebaeck
Independent Chairman of the Board5.42yrskr200.00k7.95% SEK27.1m
Paula Zeilon
Independent Director0.42yrno datano data
Paul Yianni
Independent Director0.42yrno datano data
Anki Hager
Director1.08yrskr1.59m1.79% SEK6.1m
Laura Chirica
Independent Director3.42yrskr100.00kno data
Ian Kimber
Independent Director5.42yrskr100.00k0.0070% SEK23.9k

2.4yrs

Average Tenure

57yo

Average Age

Experienced Board: SENZA's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.7%.


Top Shareholders

Company Information

SenzaGen AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SenzaGen AB
  • Ticker: SENZA
  • Exchange: OM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr340.654m
  • Shares outstanding: 21.36m
  • Website: https://senzagen.com

Location

  • SenzaGen AB
  • Building 401
  • Scheelevägen 2
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SENZAOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKSep 2017
SZGE.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDSep 2017

Biography

SenzaGen AB markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals, complex mixtures, and cosmetic ingredients in Sweden and internationally. It offers GARDskin for predicting the ability of chemicals to induce sensitization; GARDpotency, an animal free test to subcategorize sensitizers according to CLP/GHS classifications by monitoring the expression of 50 complementary genomic biomarkers; and GARDair, an in vitro assay for the prediction of chemical respiratory sensitizers. The company also provides GARDskin medical devices. It offers services through distributors, laboratories, and licensed contract research organizations. SenzaGen AB has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was founded in 2010 and is headquartered in Lund, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/04 00:47
End of Day Share Price2020/06/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.